Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 380, Issue 2, 2009, Pages 169-177

  Singh, Ranjana ^a   Srivastava, Aneesh ^a   Kapoor, Rakesh ^a   K Sharma, Raj ^a   D Mittal, Rama ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Cyclosporine A; CYP3A4; CYP3A5; Gene polymorphism; Renal transplantation; Tacrolimus

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CHILD; DRUG BLOOD LEVEL; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INDIA; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS;

ADOLESCENT; ADULT; CALCINEURIN; CHILD; CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDIA; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS; YOUNG ADULT;

EID: 67449141674     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-009-0415-y     Document Type: Article

References (35)

1. N Ahsan C Johnson T Gonwa 2001 Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years Transplantation 72 245 250 (Pubitemid 32729343)
2. L Bäckman MF Levy G Klintmalm 1995 Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group Transplant Proc 27 1124 1124
3. FC Chou SJ Tzeng JD Huang 2001 Genetic polymorphism of cytochrome P450 3A5 in Chinese Drug Metab Dispos 29 1205 1209
4. Y Dai MF Hebert N Isoherranen 2006 Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro Drug Metab Dispos 34 836 847
5. Y Dai K Iwanaga YS Lin 2004 In vitro metabolism of cyclosporine A by human kidney CYP3A5 Biochem Pharmacol 68 1889 1902 (Pubitemid 39278511)
6. CJ Dunn AJ Wagstaff CM Perry GL Plosker KL Goa 2001 Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral) 1 in organ transplantation Drugs 61 1957 2016
7. HS Eng Z Mohamed R Calne 2006 The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients Kidney Int 69 1858 1864 (Pubitemid 43739216)
8. V Haufroid M Mourad V Van Kerckhove 2004 The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients Pharmacogenetics 14 147 154 (Pubitemid 38373108)
9. V Haufroid P Wallemacq V VanKerckhove 2006 CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study Am J Transplant 6 2706 2713 (Pubitemid 44571691)
10. DA Hesselink RH van Schaik IP van der Heiden 2003 Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus Clin Pharmacol Ther 74 245 254 (Pubitemid 37083100)
11. YF Hu W Qiu ZQ Liu 2006 Effects of genetic polymorphisms of CYP3A4, CYP3A5 and MDR1 on cyclosporine pharmacokinetics after renal transplantation Clin Exp Pharmacol Physiol 33 1093 1098 (Pubitemid 44581573)
12. E Hustert M Haberl O Burk 2001 The genetic determinants of the CYP3A5 polymorphism Pharmacogenetics 11 773 779 (Pubitemid 33151512)
13. Y Jounaïdi V Hyrailles L Gervot P Maurel 1996 Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? Biochem Biophys Res Commun 221 466 470 (Pubitemid 26136494)
14. BD Kahan M Welsh L Schoenberg 1996 Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection Transplantation 62 599 606 (Pubitemid 26313901)
15. LK Kamdem F Streit UM Zanger 2005 Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus Clin Chem 51 1374 1381 (Pubitemid 41060869)
16. BP King JB Leathart E Mutch FM Williams AK Daly 2003 CYP3A5 phenotype-genotype correlations in a British population Br J Clin Pharmacol 55 625 629 (Pubitemid 36783207)
17. R Kreutz H Zürcher S Kain P Martus G Offermann J Beige 2004 The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients Pharmacogenetics 14 665 671 (Pubitemid 39411266)
18. T Kronbach V Fischer UA Meyer 1988 Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs Clin Pharmacol Ther 43 630 635 (Pubitemid 18169621)
19. P Kuehl J Zhang Y Lin 2001 Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression Nat Genet 27 383 391 (Pubitemid 32268418)
20. JK Lamba YS Lin EG Schuetz KE Thummel 2002 Genetic contribution to variable human CYP3A-mediated metabolism Adv Drug Deliv Rev 54 1271 1294 (Pubitemid 35284253)
21. SJ Lee JA Goldstein 2005 Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests Pharmacogenomics 6 357 371 (Pubitemid 40916359)
22. SJ Lee SS Lee HE Jeong 2007 The CYP3A4*18 allele, the most frequent coding variant in Asian populations, does not significantly affect the midazolam disposition in heterozygous individuals Drug Metab Dispos 35 2095 2101
23. KS Lown DG Bailey RJ Fontana 1997 Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression J Clin Invest 99 2545 2553 (Pubitemid 27227734)
24. IA Macphee S Fredericks T Tai 2002 Tacrolimus pharmacogenetics: polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement Transplantation 74 1486 1489 (Pubitemid 36014218)
25. SA Miller DD Dykes HF Polesky 1988 A simple salting out procedure for extracting DNA from human nucleated cells Nucleic Acids Res 16 1215 1215
26. LC Racusen K Solez RB Colvin 1999 The Banff 97 working classification of renal allograft pathology Kidney Int 55 713 723 (Pubitemid 29082898)
27. N Rais YK Chawla KK Kohli 2006 CYP3A phenotypes and genotypes in North Indians Eur J Clin Pharmacol 62 417 422 (Pubitemid 43873713)
28. L Renders M Frisman M Ufer I Mosyagin S Haenisch U Ott A Caliebe M Dechant F Braun U Kunzendorf I Cascorbi 2007 CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients Clin Pharmacol Ther 81 228 234 (Pubitemid 46174820)
29. C Rodríguez-Antona JG Sayi LL Gustafsson L Bertilsson M Ingelman-Sundberg 2005 Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles Biochem Biophys Res Commun 338 299 305 (Pubitemid 41540570)
30. M Sattler FP Guengerich CH Yun U Christians KF Sewing 1992 Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat Drug Metab Dispos 20 753 761
31. PS Shih JD Huang 2002 Pharmacokinetics of midazolam and 1-hydroxymidazolam in Chinese with different CYP3A5 genotypes Drug Metab Dispos 30 1491 1496
32. RH van Schaik SN de Wildt NM van Iperen AG Uitterlinden JN van den Anker J Lindemans 2000 CYP3A4-V polymorphism detection by PCR-restriction fragment length polymorphism analysis and its allelic frequency among 199 Dutch Caucasians Clin Chem 46 1834 1836 (Pubitemid 30826373)
33. RH van Schaik IP van der Heiden JN van den Anker J Lindemans 2002 CYP3A5 variant allele frequencies in Dutch Caucasians Clin Chem 48 1668 1671
34. R Venkataramanan A Swaminathan T Prasad 1995 Clinical pharmacokinetics of tacrolimus Clin Pharmacokinet 29 404 430 (Pubitemid 26004179)
35. HG Xie AJ Wood RB Kim CM Stein GR Wilkinson 2004 Genetic variability in CYP3A5 and its possible consequences Pharmacogenomics 5 243 272 (Pubitemid 38499965)